The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Ranibizumab Reduces Retinopathy Severity in Patients with Diabetic Macular Edema
After 12 or 24 monthly injections, ranibizumab, one of three currently available vascular endothelial growth factor antibodies, caused regression of diabetic retinopathy (DR) in at least 75% of patients who had diabetic macular edema and whose DR severity put them at the highest risk of progression to proliferative DR.
Andrew Hartwick from The Ohio State University: Photophobia in Traumatic Brain Injury Patients
Andrew Hartwick, PhD, Associate Professor at The College of Optometry at The Ohio State University discussed his research surrounding traumatic brain injury (TBI) patients who experience increased light sensitivity, or photophobia.
Frank Conidi: Working Toward a Safer Future in Sports Medicine
Whether it is learning from the military or finding consensus among the governing bodies of youth and scholastic sports there are steps that can be taken to make them safe and help limit the risk of injuries and concussions.
For Robin Williams, Diagnosis Came Too Late
Susan Schneider Williams, spouse of the late Robin Williams spoke with MD Magazine about the several symptoms the actor presented up to a year before his death that made it difficult to diagnose what he was suffering from: Lewy Body Disease (LBD).
Further Analysis of the Benefits of Deflazacort in Patients with Duchenne Muscular Dystrophy
Researchers at the American Academy of Neurology’s 68th Annual Meeting reported analyses of the phase III trial of the investigational glucocorticoid (deflazacort/Marathon Pharmaceuticals), which was previously found to improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.
Kate Dawson from Biogen: New Research Shows Long Term Benefits of Tecfidera
As more research is collected about Tecfidera's usage since clinical trials and approval there continue to be signs that it can be a good treatment option for patients with multiple sclerosis, especially in the earliest stages.
Fycompa: Effective Treatment for Primary Generalized Tonic-Clonic Seizures
Treating patients suffering from primary generalized tonic-clonic (PGTC) seizures with once-daily 8mg doses of adjunctive perampanel (Fycompa/Eisai) can effectively control the seizures, recent study finds.